| Year |
Title |
Altmetric |
| 2023
|
Financial Burden in Blood or Marrow Transplantation Survivors During the COVID-19 Pandemic: A BMTSS Report.
Journal of Clinical Oncology.
41:1011-1022.
2023
|
|
| 2023
|
Low c-Kit expression identifies primitive, therapy-resistant CML stem cells.
JCI Insight.
8.
2023
|
|
| 2023
|
Using Teamwork to Bridge the Adolescent and Young Adult Gap.
Jco Oncology Practice.
19:E150-E160.
2023
|
|
| 2022
|
Safe and Effective Use of Imatinib to Treat Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia During Pregnancy.
Journal of Adolescent and Young Adult Oncology.
11:617-620.
2022
|
|
| 2022
|
Autophagy inhibition impairs leukemia stem cell function in FLT3-ITD AML but has antagonistic interactions with tyrosine kinase inhibition.
Leukemia.
36:2621-2633.
2022
|
|
| 2022
|
Burden of Long-Term Morbidity Borne by Survivors of Acute Myeloid Leukemia Treated with Blood or Marrow Transplantation: The Results of the BMT Survivor Study.
Journal of Clinical Oncology.
40:3278-3288.
2022
|
|
| 2022
|
Combinatorial suicide gene strategies for the safety of cell therapies.
Frontiers in Immunology.
13.
2022
|
|
| 2022
|
Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia.
British Journal of Haematology.
198:e35-e37.
2022
|
|
| 2022
|
Assessment of Hospitalizations and Emergency Department Visits After Chimeric Antigen Receptor T-Cell Therapy Among Commercially Insured Patients.
JAMA Oncology.
8:1068-1070.
2022
|
|
| 2022
|
Trends in Late Mortality and Life Expectancy After Autologous Blood or Marrow Transplantation Over Three Decades: A BMTSS Report.
Journal of Clinical Oncology.
40:1991-2003.
2022
|
|
| 2022
|
Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia.
Leukemia Research.
117.
2022
|
|
| 2022
|
Erratum: TEMPORARY REMOVAL: PO-07: Procoagulant extracellular vesicles in patients with different types of acute leukemia (Thrombosis research PII: S0049-3848(22)00195-5)
2022
|
|
| 2022
|
Peripheral blood parameter abnormalities precede therapy-related myeloid neoplasms after autologous transplantation for lymphoma.
Cancer.
128:1392-1401.
2022
|
|
| 2022
|
Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents
2022
|
|
| 2022
|
Impact of pre-transplant individual comorbidities on risk of ICU admission and survival outcomes following allogeneic hematopoietic stem cell transplantation.
Bone Marrow Transplantation.
2022
|
|
| 2022
|
Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling.
Leukemia.
2022
|
|
| 2021
|
Fattening up FLT3-ITD for the kill.
Blood.
138:2158-2159.
2021
|
|
| 2021
|
Metabolic alterations mediated by STAT3 promotes drug persistence in CML.
Leukemia.
35:3371-3382.
2021
|
|
| 2021
|
Transcription factor MEF2D is required for the maintenance of MLL-rearranged acute myeloid leukemia.
Blood Advances.
5:4727-4740.
2021
|
|
| 2021
|
Trends in Late Mortality and Life Expectancy after Allogeneic Blood or Marrow Transplantation over 4 Decades: A Blood or Marrow Transplant Survivor Study Report.
JAMA Oncology.
7:1626-1634.
2021
|
|
| 2021
|
Methylation of dual-specificity phosphatase 4 controls cell differentiation.
Cell Reports.
36.
2021
|
|
| 2021
|
TNF-α-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signaling.
Cell Reports.
36.
2021
|
|
| 2021
|
Impact of access to care on 1-year mortality following allogeneic blood or marrow transplantation.
Bone Marrow Transplantation.
56:1364-1372.
2021
|
|
| 2021
|
Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL.
Blood.
137:471-484.
2021
|
|
| 2020
|
Exploitation of dihydroorotate dehydrogenase (DHODH) and p53 activation as therapeutic targets: A case study in polypharmacology.
Journal of Biological Chemistry.
295:17935-17949.
2020
|
|
| 2020
|
Chronic myeloid leukemia, version 2.2021.
Journal of the National Comprehensive Cancer Network : JNCCN.
18:1385-1415.
2020
|
|
| 2020
|
A high-content cytokine screen identifies myostatin propeptide as a positive regulator of primitive chronic myeloid leukemia cells.
The hematology journal : the official journal of the European Haematology Association / EHA.
105:2095-2104.
2020
|
|
| 2020
|
An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia.
Blood.
135:2337-2353.
2020
|
|
| 2020
|
Collaborative cardiovascular management of patients with chronic myeloid leukemia on tyrosine kinase inhibitors
2020
|
|
| 2020
|
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.
Journal for ImmunoTherapy of Cancer.
8.
2020
|
|
| 2020
|
CXCR4 Signaling Has a CXCL12-Independent Essential Role in Murine MLL-AF9-Driven Acute Myeloid Leukemia.
Cell Reports.
31.
2020
|
|
| 2020
|
Expenditures for First- and Second-Generation Tyrosine Kinase Inhibitors before and after Transition of Imatinib to Generic Status.
JAMA Oncology.
6:542-546.
2020
|
|
| 2020
|
Erratum: Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence of Treatment-Resistant Leukemia Stem Cells (Cell Stem Cell (2019) 24(5) (769–784.e6), (S1934590919300700), (10.1016/j.stem.2019.02.018)).
Cell Stem Cell.
26:123.
2020
|
|
| 2019
|
Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report.
Cancer.
125:4033-4042.
2019
|
|
| 2019
|
Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia.
Cancer.
125:2570-2578.
2019
|
|
| 2019
|
Mapping Distinct Bone Marrow Niche Populations and Their Differentiation Paths.
Cell Reports.
28:302-311.e5.
2019
|
|
| 2019
|
Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence of Treatment-Resistant Leukemia Stem Cells.
Cell Stem Cell.
24:769-784.e6.
2019
|
|
| 2019
|
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.
Nature Genetics.
51:296-307.
2019
|
|
| 2019
|
SIRT1 regulates metabolism and leukemogenic potential in CML stem cells.
Journal of Clinical Investigation.
129:2685-2701.
2019
|
|
| 2019
|
TARGETING LEUKEMIA STEM CELL RESISTANCE IN CHRONIC MYELOGENOUS LEUKEMIA.
Transactions of the American Clinical and Climatological Association.
130:246-254.
2019
|
|
| 2018
|
A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.
Nature Communications.
9.
2018
|
|
| 2018
|
Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in Childhood.
JAMA Oncology.
4.
2018
|
|
| 2018
|
Cord Blood Thyroid-Stimulating Hormone Level: Interpretation in Light of Antenatal and Perinatal Factors.
Journal of Neonatology.
32:87-92.
2018
|
|
| 2018
|
Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage (Nature Communications (2018) DOI: 10.1038/s41467-018-03441-3).
Nature Communications.
9.
2018
|
|
| 2018
|
Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2.
Leukemia.
32:2706-2709.
2018
|
|
| 2018
|
Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplant.
Bone Marrow Transplantation.
53:1345-1348.
2018
|
|
| 2018
|
SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function.
Cell Stem Cell.
23:355-369.e9.
2018
|
|
| 2018
|
Chronic myeloid leukemia, version 1.2019.
Journal of the National Comprehensive Cancer Network : JNCCN.
16:1108-1135.
2018
|
|
| 2018
|
Late mortality after autologous blood or marrow transplantation in childhood: A Blood or Marrow Transplant Survivor Study-2 report.
Blood.
131:2720-2729.
2018
|
|
| 2018
|
Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells.
Cell Reports.
23:3127-3136.
2018
|
|
| 2018
|
Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.
Nature Medicine.
24:450-462.
2018
|
|
| 2018
|
JMJD1B Demethylates H4R3me2s and H3K9me2 to Facilitate Gene Expression for Development of Hematopoietic Stem and Progenitor Cells.
Cell Reports.
23:389-403.
2018
|
|
| 2018
|
hsa-mir183/EGR1–mediated regulation of E2F1 is required for CML stem/progenitor cell survival.
Blood.
131:1532-1544.
2018
|
|
| 2018
|
Autophagic flux blockage by accumulation of weakly basic tenovins leads to elimination of B-Raf mutant tumour cells that survive vemurafenib.
PLoS One.
13.
2018
|
|
| 2018
|
Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion.
Leukemia.
32:575-587.
2018
|
|
| 2018
|
Congenital Hypothyroid Screening in Term Neonates Using Cord Blood TSH.
Journal of Neonatology.
32:12-14.
2018
|
|
| 2018
|
Congenital hypothyroidism screening in term neonates using umbilical cord blood TSH values.
Indian Journal of Endocrinology and Metabolism.
22:277-279.
2018
|
|
| 2018
|
Preservation of quiescent chronic myelogenous leukemia stem cells by the bone marrow microenvironment.
Advances in Experimental Medicine and Biology.
1100:97-110.
2018
|
|
| 2017
|
Novel approaches to therapy in CML.
Hematology.
2017:115-120.
2017
|
|
| 2017
|
The T-ALL related gene BCL11B regulates the initial stages of human T-cell differentiation.
Leukemia.
31:2503-2514.
2017
|
|
| 2017
|
Myeloproliferative neoplasms, version 2.2018 featured Updates to the NCCN guidelines.
Journal of the National Comprehensive Cancer Network : JNCCN.
15:1193-1207.
2017
|
|
| 2017
|
Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.
Journal of Clinical Investigation.
127:2392-2406.
2017
|
|
| 2017
|
Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma.
Journal of Clinical Oncology.
35:1598-1605.
2017
|
|
| 2017
|
Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI.
Blood.
129:1008-1020.
2017
|
|
| 2017
|
Autologous hematopoietic stem cell transplantation in lymphoma patients is associated with a decrease in the double strand break repair capacity of peripheral blood lymphocytes.
PLoS One.
12.
2017
|
|
| 2017
|
High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.
Journal of Clinical Oncology.
35:394-401.
2017
|
|
| 2017
|
Correction: In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia..
PLoS One.
12:e0172640.
2017
|
|
| 2017
|
Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
Oncotarget.
8:10809-10821.
2017
|
|
| 2017
|
Hoxa9 and Hoxa10 induce CML myeloid blast crisis development through activation of Myb expression.
Oncotarget.
8:98853-98864.
2017
|
|
| 2017
|
Impact of chromosomal rearrangement upon DNA methylation patterns in leukemia.
Central European Journal of Medicine.
12:76-85.
2017
|
|
| 2016
|
Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells.
Blood.
128:2671-2682.
2016
|
|
| 2016
|
In vitro pre-clinical validation of suicide gene modified anti-CD33 redirected chimeric antigen receptor T-cells for acute myeloid leukemia.
PLoS One.
11.
2016
|
|
| 2016
|
Myeloproliferative neoplasms, version 2.2017: Clinical Practice Guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN.
14:1572-1611.
2016
|
|
| 2016
|
Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia.
Nature Communications.
7.
2016
|
|
| 2016
|
Increased urinary frequency due to P. falciparum infection - A case report.
Journal of Clinical and Diagnostic Research.
10:SL02.
2016
|
|
| 2016
|
Leukemoid Reaction due to P. falciparum Infection.
Indian Journal of Pediatrics.
83:1501-1502.
2016
|
|
| 2016
|
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.
Science Translational Medicine.
8.
2016
|
|
| 2016
|
Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia.
Scientific Reports.
6.
2016
|
|
| 2016
|
Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells.
Journal of Clinical Investigation.
126:975-991.
2016
|
|
| 2016
|
Haemophagocytic syndrome in a four year old male child with plasmodium vivax infection.
Journal of Nepal Paediatric Society.
36:193-195.
2016
|
|
| 2016
|
Neonatal leukemoid reaction - a diagnostic dilemma.
Journal of Nepal Paediatric Society.
36:298-299.
2016
|
|
| 2015
|
HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation.
Cell Stem Cell.
17:597-610.
2015
|
|
| 2015
|
Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia
2015
|
|
| 2015
|
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
Mayo Clinic Proceedings.
90:996-1000.
2015
|
|
| 2015
|
Role of SIRT1 in the growth and regulation of normal hematopoietic and leukemia stem cells.
Current Opinion in Hematology.
22:324-329.
2015
|
|
| 2015
|
Osteoblast ablation reduces normal long-term hematopoietic stem cell self-renewal but accelerates leukemia development.
Blood.
125:2678-2688.
2015
|
|
| 2015
|
MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors.
Blood.
125:1302-1313.
2015
|
|
| 2015
|
Influence of Bone Marrow Microenvironment on Leukemic Stem Cells: Breaking Up an Intimate Relationship.
Advances in Cancer Research.
127:227-252.
2015
|
|
| 2014
|
Pushing the limits: Defeating leukemia stem cells by depleting telomerase.
Cell Stem Cell.
15:673-675.
2014
|
|
| 2014
|
Altered microenvironmental regulation of CML stem cells.
2014
|
|
| 2014
|
Leukemia cells make ruthless competitors.
Blood.
124:2900-2901.
2014
|
|
| 2014
|
JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.
Blood.
124:1492-1501.
2014
|
|
| 2014
|
Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.
Blood.
123:2826-2837.
2014
|
|
| 2014
|
Granulocytes affect double-strand break repair assays in primary human lymphocytes.
PLoS One.
9.
2014
|
|
| 2014
|
Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity.
Blood.
123:15-25.
2014
|
|
| 2014
|
ATRA-Induced Cellular Differentiation and CD38 Expression Inhibits Acquisition of BCR-ABL Mutations for CML Acquired Resistance.
PLoS Genetics.
10.
2014
|
|
| 2014
|
Iron chelators induce autophagic cell death in multiple myeloma cells.
Leukemia Research.
38:988-996.
2014
|
|
| 2014
|
SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells.
Cell Stem Cell.
15:431-446.
2014
|
|
| 2013
|
T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.
Blood.
122:3138-3148.
2013
|
|
| 2013
|
PP2A-activating drugs selectively eradicate tki-resistant chronic myeloid leukemic stem cells.
Journal of Clinical Investigation.
123:4144-4157.
2013
|
|
| 2013
|
Roles of SIRT1 in leukemogenesis.
Current Opinion in Hematology.
20:308-313.
2013
|
|
| 2013
|
Stem cell therapy: A clinical trial of stroke.
Clinical Neurology and Neurosurgery.
115:1003-1008.
2013
|
|
| 2013
|
Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.
Blood.
121:4175-4183.
2013
|
|
| 2013
|
Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.
Blood.
121:1824-1838.
2013
|
|
| 2013
|
A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.
EMBO Molecular Medicine.
5:353-365.
2013
|
|
| 2013
|
TLR9-mediated siRNA delivery for Targeting of normal and malignant human hematopoietic cells in vivo.
Blood.
121:1304-1315.
2013
|
|
| 2013
|
SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells.
Oncogene.
32:589-598.
2013
|
|
| 2013
|
Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation.
Blood.
122:3335-3339.
2013
|
|
| 2013
|
The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents.
Blood.
122:1900-1913.
2013
|
|
| 2013
|
The controversial role of Sirtuins in tumorigenesis-SIRT7 joins the debate.
Cell Research.
23:10-12.
2013
|
|
| 2012
|
Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation
2012
|
|
| 2012
|
Hereditary leukemia due to rare RUNX1c splice variant (L472X) presents with eczematous phenotype..
International Journal of Clinical Medicine.
3.
2012
|
|
| 2012
|
Intrathoracic airway obstruction and gastroesophageal reflux: A canine model.
Pediatric pulmonology. Supplement.
47:1097-1102.
2012
|
|
| 2012
|
Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis.
Leukemia Research.
36:1152-1156.
2012
|
|
| 2012
|
Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors.
Leukemia Research.
36:966-973.
2012
|
|
| 2012
|
Chronic myelogenous leukemia stem and progenitor cells demonstrate chromosomal instability related to repeated breakage-fusion-bridge cycles mediated by increased nonhomologous end joining.
Blood.
119:6187-6197.
2012
|
|
| 2012
|
Setbp1 promotes the self-renewal of murine myeloid progenitors via activation of Hoxa9 and Hoxa10.
Blood.
119:6099-6108.
2012
|
|
| 2012
|
Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia.
Cancer Cell.
21:577-592.
2012
|
|
| 2012
|
Genetic susceptibility to therapy-related leukemia after Hodgkin lymphoma or non-Hodgkin lymphoma: Role of drug metabolism, apoptosis and DNA repair.
Blood Cancer Journal.
2.
2012
|
|
| 2012
|
Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis.
Blood.
119:1904-1914.
2012
|
|
| 2012
|
Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib.
Cancer Cell.
21:266-281.
2012
|
|
| 2012
|
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
Blood.
119:1501-1510.
2012
|
|
| 2012
|
Overcoming CML acquired resistance by specific inhibition of Aurora a kinase in the KCL-22 cell model.
Carcinogenesis.
33:285-293.
2012
|
|
| 2012
|
Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat5 signaling.
Molecular Oncology.
6:276-283.
2012
|
|
| 2011
|
Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment.
Blood.
118:5565-5572.
2011
|
|
| 2011
|
Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice.
Blood.
118:2159-2169.
2011
|
|
| 2011
|
Acritical role for SHP2 in STAT5 activation and growth factor-mediated proliferation, survival, and differentiation of human CD34+ cells.
Blood.
118:1504-1515.
2011
|
|
| 2011
|
Stem cell quiescence.
Clinical Cancer Research.
17:4936-4941.
2011
|
|
| 2011
|
The LRF transcription factor regulates mature B cell development and the germinal center response in mice.
Journal of Clinical Investigation.
121:2583-2598.
2011
|
|
| 2011
|
NMR-based metabolomic analysis of the molecular pathogenesis of therapy-related myelodysplasia/acute myeloid leukemia.
Journal of Proteome Research.
10:2873-2881.
2011
|
|
| 2011
|
Treatment-related myelodysplastic syndrome: Molecular characteristics and therapy.
Current Opinion in Hematology.
18:77-82.
2011
|
|
| 2011
|
Altered Hematopoietic Cell Gene Expression Precedes Development of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia and Identifies Patients at Risk.
Cancer Cell.
20:591-605.
2011
|
|
| 2011
|
Inhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediated MAPK activation and transformation of primary human hematopoietic cells.
Leukemia.
25:305-312.
2011
|
|
| 2011
|
Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia.
Leukemia.
25:463-472.
2011
|
|
| 2010
|
Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate.
Cancer Cell.
17:427-442.
2010
|
|
| 2010
|
Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.
Blood.
115:2241-2250.
2010
|
|
| 2010
|
miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts.
Cell.
140:652-665.
2010
|
|
| 2010
|
BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia.
Journal of Biological Chemistry.
285:5085-5096.
2010
|
|
| 2010
|
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
Leukemia.
24:1299-1301.
2010
|
|
| 2010
|
Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors.
Leukemia.
24:779-787.
2010
|
|
| 2009
|
Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma.
Journal of Clinical Oncology.
27:791-798.
2009
|
|
| 2009
|
Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells.
Experimental Hematology.
37:206-214.
2009
|
|
| 2008
|
Effects of dasatinib on Src kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
Cancer Research.
68:9624-9633.
2008
|
|
| 2008
|
Excellent supervision.
New scientist (1971).
200:19.
2008
|
|
| 2008
|
Gene expression pattern in myelodyplasia underline the role of apoptosis and differentiation in disease initiation and progression.
Translational Oncogenomics.
2008:137-149.
2008
|
|
| 2008
|
The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells.
Blood.
111:5093-5100.
2008
|
|
| 2008
|
Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.
Blood.
111:2329-2338.
2008
|
|
| 2008
|
CREB is a critical regulator of normal hematopoiesis and leukemogenesis.
Blood.
111:1182-1192.
2008
|
|
| 2008
|
Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors.
Leukemia.
22:748-755.
2008
|
|
| 2007
|
Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
Transfusion.
47:2207-2216.
2007
|
|
| 2007
|
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Blood.
110:3540-3546.
2007
|
|
| 2007
|
Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Bone Marrow Transplantation.
40:843-850.
2007
|
|
| 2007
|
Kangaroo Mother Care (KMC) in LBW infants - A western Rajasthan experience.
Indian Journal of Pediatrics.
74:747-749.
2007
|
|
| 2007
|
BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia.
Cancer Research.
67:7045-7053.
2007
|
|
| 2007
|
Monitoring repair of DNA damage in cell lines and human peripheral blood mononuclear cells.
Analytical Biochemistry.
365:246-259.
2007
|
|
| 2007
|
Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells.
Blood.
109:5411-5421.
2007
|
|
| 2007
|
Low birth weight and insulin resistance in mid and late childhood.
Indian Pediatrics.
44:177-184.
2007
|
|
| 2007
|
The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia.
Blood.
109:1782-1789.
2007
|
|
| 2007
|
Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment.
Cancer Research.
67:1113-1120.
2007
|
|
| 2007
|
Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone.
Leukemia Research.
31:261-265.
2007
|
|
| 2007
|
Rheumatoid neuropathy.
Indian Journal of Rheumatology.
2:45-46.
2007
|
|
| 2006
|
Escaping inhibition by self-mutation.
Blood.
108:7.
2006
|
|
| 2006
|
Soil solarization for managing weeds in brinjal (Solanum melongena) nursery.
Indian Journal of Agricultural Sciences.
76:129-131.
2006
|
|
| 2005
|
Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma.
Journal of Clinical Oncology.
23:6699-6711.
2005
|
|
| 2005
|
Pediatric HIV infection/AIDS in Agra [2].
Indian Pediatrics.
42:953-954.
2005
|
|
| 2005
|
Expression of DLK1 in hematopoietic cells results in inhibition of differentiation and proliferation.
Oncogene.
24:4472-4476.
2005
|
|
| 2005
|
Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease.
Biology of Blood and Marrow Transplantation.
11:307-313.
2005
|
|
| 2005
|
Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.
Blood.
105:2093-2098.
2005
|
|
| 2005
|
Keratomalacia in a neonate secondary to maternal vitamin A deficiency.
Indian Journal of Pediatrics.
72:881-882.
2005
|
|
| 2005
|
Nonproliferating CML CD34+ progenitor are resistant to apoptosis induced by a wide range of proapoptotic stimuli.
Leukemia.
19:1034-1041.
2005
|
|
| 2005
|
Reproducibility, fidelity, and discriminant validity of mRNA amplification for microarray analysis from primary hematopoietic cells
2005
|
|
| 2004
|
Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: Results from the Bone Marrow Transplant Survivor Study.
Blood.
104:1898-1906.
2004
|
|
| 2004
|
Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors.
Cancer Research.
64:5322-5331.
2004
|
|
| 2004
|
Autologous hematopoietic cell transplantation for chronic myelogenous leukemia
2004
|
|
| 2004
|
BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Blood.
103:3167-3174.
2004
|
|
| 2004
|
Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells
2004
|
|
| 2003
|
Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed.
Biology of Blood and Marrow Transplantation.
9:649-656.
2003
|
|
| 2003
|
Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed..
Biology of Blood and Marrow Transplantation.
9:649-656.
2003
|
|
| 2003
|
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
Blood.
101:4701-4707.
2003
|
|
| 2003
|
A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: Impact of cytogenetic characteristics on transplantation outcome.
Biology of Blood and Marrow Transplantation.
9:766-771.
2003
|
|
| 2002
|
Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation.
Blood.
99:3792-3800.
2002
|
|
| 2002
|
Contact with fibronectin enhances preservation of normal but not chronic myelogenous leukemia primitive hematopoietic progenitors.
Experimental Hematology.
30:324-332.
2002
|
|
| 2001
|
Abnormal growth factor modulation of β1-integrin-mediated adhesion in chronic myelogenous leukaemia haematopoietic progenitors.
British Journal of Haematology.
115:845-853.
2001
|
|
| 2001
|
Solid cancers after bone marrow transplantation.
Journal of Clinical Oncology.
19:464-471.
2001
|
|
| 2000
|
Amifostine (ETHOYL) in Combination with topotecan and ARA-C for patients with poor risk myelodysplasia (MDS) and secondary acute myelogenous leukemia.
Blood.
96.
2000
|
|
| 2000
|
Chronic myelogenous leukemia primitive hematopoietic progenitors demonstrate increased sensitivity to growth factor-induced proliferation and maturation.
Experimental Hematology.
28:1401-1412.
2000
|
|
| 2000
|
Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factors.
Blood.
95:1588-1593.
2000
|
|
| 2000
|
Autologous Stem-Cell Transplantation for Poor-Risk and Relapsed Intermediate- and High-Grade Non-Hodgkin's Lymphoma.
Clinical Lymphoma, Myeloma and Leukemia.
1:46-54.
2000
|
|
| 2000
|
Effects of Allogeneic Bone Marrow Transplantation on Recipient Bone Mineral Density: A Prospective Study.
Biology of Blood and Marrow Transplantation.
6:344-351.
2000
|
|
| 2000
|
Effects of allogeneic bone marrow transplantation on recipient bone mineral density: A prospective study..
Biology of Blood and Marrow Transplantation.
6:344-351.
2000
|
|
| 1999
|
Role of abnormal integrin-cytoskeletal interactions in impaired β1 integrin function in chronic myelogenous leukemia hematopoietic progenitors.
Experimental Hematology.
27:1384-1396.
1999
|
|
| 1999
|
Recombinant human thrombopoietin in combination with granulocyte colony- stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy.
Blood.
93:2798-2806.
1999
|
|
| 1999
|
High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced-stage Hodgkin's disease during first partial or complete remission.
Biology of Blood and Marrow Transplantation.
5:292-298.
1999
|
|
| 1999
|
Stromal extracellular matrix components as growth regulators for human hematopoietic progenitors.
Hematology.
4:321-333.
1999
|
|
| 1999
|
The Hematopoietic Microenvironment: Stromal Extracellular Matrix Components As Growth Regulators For Human Hematopoietic Progenitors..
Hematology.
4:321-333.
1999
|
|
| 1998
|
Comparative analysis of autografting in chronic myelogenous leukemia: Effects of priming regimen and marrow or blood origin of stem cells.
Blood.
92:1820-1831.
1998
|
|
| 1998
|
Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores β1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors.
Blood.
91:3414-3422.
1998
|
|
| 1998
|
Autologous transplantation for the treatment of chronic myelogenous leukemia
1998
|
|
| 1998
|
Interferon-α restores β1-integrin-dependent, collagen-mediated platelet aggregation in a patient with chronic myelogenous leukemia
1998
|
|
| 1998
|
The effect of interferon-α on beta-1 integrin mediated adhesion and growth regulation in chronic myelogenous leukemia
1998
|
|
| 1998
|
Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores β1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors.
Leukemia.
12:1708-1717.
1998
|
|
| 1997
|
Abnormal pi integrin function in cml progenitors is related to enhanced receptor attachment to the cytoskeleton.
Experimental Hematology.
25:757.
1997
|
|
| 1997
|
Defective progenitor/stroma interactions in the pathogenesis of chronic myeloid leukemia.
Experimental Hematology.
25:874.
1997
|
|
| 1997
|
A clinically suitable ex vivo expansion culture system for LTC-IC and CFC using stroma-conditioned medium.
Experimental Hematology.
25:980-991.
1997
|
|
| 1997
|
Autologous transplantation therapy for chronic myelogenous leukemia.
Blood.
89:2623-2634.
1997
|
|
| 1997
|
Autologous stem cell transplantation for the treatment of chronic myelogenous leukemia..
Cancer Treatment and Research.
77:357-374.
1997
|
|
| 1997
|
Integrin-mediated regulation of hematopoiesis: Do bcr/abl-lnduced defects in integrin function underlie the abnormal circulation and proliferation of cml progenitors?.
Acta Haematologica.
97:40-52.
1997
|
|
| 1997
|
Pathophysiology of CML: Do defects in integrin function contribute to the premature circulation and massive expansion of the BCR/ABL positive clone?
1997
|
|
| 1996
|
CML progenitor adhesion and adhesion-mediated proliferation inhibition is restored by tyrphostin ag957, a protein tyrosine kinase inhibitor with activity against the BCR-ABL kinase.
Experimental Hematology.
24:1131.
1996
|
|
| 1996
|
BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients.
Blood.
87:4770-4779.
1996
|
|
| 1996
|
Cyclophosphamide/GM-CSF priming in autotransplant therapy for CML.
Bone Marrow Transplantation.
17.
1996
|
|
| 1996
|
Interferon-α restores normal β1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia.
Blood.
87:3883-3891.
1996
|
|
| 1995
|
Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: Role of malignant stromal macrophages.
Blood.
85:3636-3645.
1995
|
|
| 1995
|
Autografting for chronic myelogenous leukemia..
Current Opinion in Hematology.
2:436-443.
1995
|
|
| 1995
|
T lymphocytes cultured from chronic myelogenous leukemia bone marrow suppress autologous hematopoietic progenitors.
Leukemia.
9:1006-1012.
1995
|
|
| 1995
|
Treatment of marrow stroma with interferon-α restores normal β1 integrin-dependent adhesion of chronic myelogenous leukemia hematopoietic progenitors: Role of MIP-1α.
Journal of Clinical Investigation.
96:931-939.
1995
|
|
| 1994
|
Interferon-α restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired β1 integrin receptor function.
Journal of Clinical Investigation.
94:384-391.
1994
|
|
| 1994
|
Role of bone marrow matrix in normal and abnormal hematopoiesis
1994
|
|
| 1990
|
Immunologic and immunogenetic studies in rheumatic fever and rheumatic heart disease.
Indian Journal of Pediatrics.
57:693-700.
1990
|
|
| 1990
|
Fluorides in urolithiasis - A preliminary survey.
Indian Journal of Urology.
7:22-24.
1990
|
|
| 1989
|
Prenatal diagnosis of Tay-Sachs disease..
Indian Pediatrics.
26:1052-1053.
1989
|
|
| 1989
|
Citrullinemia: early diagnosis & successful management of an otherwise lethal disorder..
Indian Pediatrics.
26:589-592.
1989
|
|
| 1989
|
Lymphocyte subsets in acute rheumatic fever and rheumatic heart disease
1989
|
|
